Martin Low

Martin Low has founded or co-founded eight companies including his most recent, On Target Labs, where he served as CEO for 9 years. Under his leadership, two drugs have been brought into the clinic and the lead drug has been filed with the FDA for approval in ovarian cancer and is in a phase 3 trial for lung cancer. To fund development, he raised $90M and secured partnerships with key Medtech companies. Martin has introduced several products that have won awards from Business Week, The Thomas Edison Foundation and the Smithsonian Institute. Martin has degrees from Purdue University and Northwestern’s Kellogg Graduate School of Management.